Source: Two ResMed external clinical studies of experienced PAP patients. The first study included users with ≥ 6 months’ therapy who used ResMed’s AirFit F40 and AirFit F20 full face masks in randomized order for up to seven consecutive nights each at home. Study conducted in Australia, June 6 – 27, 2023, n=28 (AirFit F40) and 29 (AirFit F20). Facial measurements of 29 participants were taken. The second study included current users with ≥ 12 months’ PAP therapy who met 90-day CMS compliance for PAP therapy in the three months prior to the study. Participants used ResMed’s AirFit F40 and Fisher & Paykel’s Evora Full in a randomized order with their own for up to seven consecutive nights each at home. Study conducted in the U.S., October 4 – November 20, 2023, n=57. Facial measurements of 57 participants were taken.

Source: Internal ResMed comparison of the ResMed AirFit F20, AirTouch F20, AirFit F30 and AirFit F40. Measurements are based on cushion mask on face, front view and side view.

Source: Testimonial from two ResMed external clinical studies of experienced PAP patients. The first study included users with ≥ 6 months’ therapy who used ResMed’s AirFit F40 and AirFit F20 full face masks in randomized order for up to seven consecutive nights each at home. Study conducted in Australia, June 6 – 27, 2023, n=28 (AirFit F40) and 29 (AirFit F20). Facial measurements of 29 participants were taken. The second study included current users with ≥ 12 months’ PAP therapy who met 90-day CMS compliance for PAP therapy in the three months prior to the study. Participants used ResMed’s AirFit F40 and Fisher & Paykel’s Evora Full in a randomized order with their own for up to seven consecutive nights each at home. Study conducted in the U.S., October 4 – November 20, 2023, n=57. Facial measurements of 57 participants were taken.